What are GLP-1 drugs and why are they so important?
GLP-1 agonists mimic a gut satiety hormone — Wegovy produced 18.8% average weight loss in 72 weeks — with Novo near $50 billion from Ozempic and Wegovy by 2024 and Zepbound at $4 billion in a single quarter in early 2026.
GLP-1 stands for glucagon-like peptide-1, a hormone produced in the gut that signals fullness and helps regulate blood sugar. GLP-1 drugs mimic this hormone. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the leading products, used for diabetes and obesity. High-dose Wegovy produced average weight loss of about 18.8% in a 72-week trial. Demand has been enormous: Novo had made nearly $50 billion from Ozempic and Wegovy by 2024, and Zepbound recorded $4 billion in sales in a single quarter in early 2026. Epidemiologists cited by Senator Sanders estimated that more than 40,000 lives a year could be saved if weight-loss drugs were affordable and widely available. Their scale means pricing decisions for these drugs have major consequences for Medicare, employers and household budgets.